ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
124.91
-3.09 (-2.41%)
Jul 28, 2026, 12:10 PM EDT - Market open
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 1.34M EUR in the quarter ending March 31, 2026, with 35.21% growth. This brings the company's revenue in the last twelve months to 4.92M, down -59.82% year-over-year. In the year 2025, ABIVAX Société Anonyme had annual revenue of 4.57M, down -63.22%.
Revenue (ttm)
4.92M EUR
Revenue Growth
-59.82%
P/S Ratio
1,956.69
Revenue / Employee
61,500 EUR
Employees
80
Market Cap
11.10B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.57M | -7.86M | -63.22% |
| Dec 31, 2024 | 12.43M | 7.85M | 171.67% |
| Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
| Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
| Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.24B |
| Halozyme Therapeutics | 1.51B |
| Bio-Techne | 1.21B |
| Madrigal Pharmaceuticals | 1.13B |
| Corcept Therapeutics | 769.10M |
| Axsome Therapeutics | 708.24M |
| Arrowhead Pharmaceuticals | 622.01M |
| Krystal Biotech | 417.30M |
ABVX News
- 4 days ago - Abivax price target raised to $180 from $132 at Morgan Stanley - TheFly
- 18 days ago - Abivax Secures Funding to Advance Ulcerative Colitis Drug (ABVX) - GuruFocus
- 18 days ago - Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC - CNBC
- 18 days ago - Best defense is the offence, says Abivax CEO after takeover speculation - CNBC
- 18 days ago - ABIVAX Société Anonyme Slides: Corporate presentation - Filings
- 19 days ago - Abivax price target raised to $175 from $165 at Piper Sandler - TheFly
- 20 days ago - Abivax: Wall Street Catches Up to the Data - MarketBeat
- 21 days ago - Abivax Announces Closing of $920 Million Public Offering - GlobeNewsWire